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Background: Although microRNAs offer great potential as cancer biomarkers, effective clinical dignostics and
tumor maker have not been verified to diagnose with colorectal cancer (CRC). The purpose of our study is to
systematically assess the expression of miRNAs in matched cancer and normal tissue samples to identify promising
diagnostic microRNA (miRNA) biomarkers for CRC.
Methods: In our study, we examined by Real-Time PCR the expression levels of 96 mature miRNA in 32 CRC patients
with differently expressed tumors versus normal colon tissues. Using enter and stepwise variable selection methods
separately, conditional logistic regression was conducted to identify miRNAs associated with CRC. The classification
performance of these indicators was assessed under the Fisher discriminant analysis. Receiver operating characteristic
curve analyses were applied to obtain diagnostic utility of the differentially expressed miRNAs.
Results: In this study, we confirmed 11 overexpressed miRNAs with no less than twofold difference, and 85
downexpressed miRNAs with up to 0.5-fold difference in CRC from 96 aberrantly expressed miRNAs being identified by
real-time PCR. Conditional logistic regression results confirmed that miRNA-378 and miRNA-145 expression profile was
statistically significant. The error diagnosis rate of these two miRNAs are 0.194 and 0.113, separeately, showing by
discriminant analysis.
Conclusions: MiRNA-145 and miRNA-378* are potential biomarkers for early detection of CRC, which may help in
diagnosing CRC in early period.
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Colorectal cancer (CRC) yields the second highest mor-
tality rate in China, showing a high incidence trend.
Early diagnosis and treatment of CRC is an effective way
to improve patients’ survival. However, most cases are
diagnosed with CRC at late stages as current clinical
diagnostics and tumor markers are inconvenient and
population screening rates are low. Therefore, there is
an imperative need to search for specific, sensitive bio-
markers for the early diagnosis of CRC.* Correspondence: chliyang2008@sina.com
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Growing studies suggests that microRNA (miRNA) plays
an important role in colon disease process, including
cell differention, development, proliferation and trans-
lation. Futhermore, misregulation of miRNA expression
might contribute to human diseases. Evidence has shown
that miRNA can work with the target mRNA 3′ non-
transcribed with incomplete or complete pairing and
negatively regulate gene expression in post-transcriptional
level by degrading the target mRNA or inhibit transla-
tion [1].
There is increasing evidence that some miRNAs may
be used as diagnostic biomarkers for CRC by identifyinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and ajacent non-neoplastic tissues from patients. For ex-
ample, E Bandrés et al. reported that miR-31, miR-96,
miR-133b, miR-135b, miR-145, and miR-183 are the
most significantly deregulated miRNAs and the expres-
sion level of miR-31 was correlated with the stage of
CRC tumor [2]. Calin et al. reported that one of the
most upregulated miRNAs is miR-106a, which is con-
sistently reported in six studies, and the five most down-
regulated miRNAs are miR-30a-3p, miR-139, miR-145,
miR-125a, and miR-133a, which are consistently re-
ported and differentially expressed in four studies; these
miRNAs may actually be of clinical use as diagnostic/
prognostic biomarkers or therapeutic targets [3]. How-
ever, most of the screening studies have small sample
with no prediction accuracy of candidate diagnostic
biomarkers.
To determine much sensitive indicators, the present
study examined the expression of 96 mature miRNAs in
a panel of 31 matched pairs of tumoral and non-tumoral
tissues by real-time PCR. Conditional logistic regression
was used to screen the factors contributed to the occur-
rence of tumor, among which miR-145 and miR-378*
were found being statistically significant. Futher analysis
reveals miR-378* and miR-145 exhibits potential as a
good diagnostic and prognostic marker.
Methods
To investigate whether miRNAs are differentially expressed
in CRC versus normal colon tissues, surgical specimens of
cancer tissue and adjacent normal mucosa were obtained
from 32 patients with colorectal cancer who underwent
surgery at The General Hospital of PLA Guangzhou
Military Area between 2012 and 2013. Fresh CRC and adja-
cent noncancerous colorectal tissues, which were used as
specimens, were obtained by experienced surgeons and
examined by experienced pathologists. Surgery was per-
formed to remove the primary tumor immediately after
carcinoma was diagnosed. Incision was performed from the
edge of the site by at least 2 cm. Tumor stage was classified
according to the International Union against Cancer
(UICC, 6th ed., 2002). Informed written consent was
obtained from each patient, and research protocols were
approved by the Medical Ethics Committee of the General
Hospital of PLA Guangzhou Military Area.
RNA extraction was performed to obtain cryopre-
served tissues and adjacent group-woven sliced tissues
with liquid nitrogen, grinding into powerder using Trizol
total RNA isolation reagent as per the manufacturer’s
protocal [4]. Concentration and purity of isolated RNA
were assessed by measuring the optical density at 260
(OD260) and 280 nm (OD280).
Isolated RNA was of high purity and integrity. A260/
A280 ratios for the human genomic DNA extractedfrom spit were consistently within generally acceptable
values of 1.7 to 2.0 [5]. Reverse transcription-related op-
erations were performed following the kit instructions.
Quantification was performed by real-time PCR using
SYBR Premix Ex Taq TM (TaKaRa) for the most upregu-
lated or most downregulated miRNAs. The primers for
U6 were obtained from TaKaRa. PCR was performed in
a real-time PCR system (Bio-Rad) with the following re-
action conditions: Real-time PCR kit was operated in
strict accordance with the manufacturer’s instructions.
The cycling program consists of 1× at 95°C for 10 min
and 40× (15 s at 95°C) at 60°C, plus extension of 60 s,
for a total of 40 cycles [6].
Default threshold settings were used as threshold cycle
(Ct) data. The Ct is the fractional cycle number at which
the fluorescence passes the fixed threshold [7]. After cal-
culating the Ct value, expression values were normalized
to those for U6, which were calculated as ΔCt = Ct −CtU6
(expression of the relative expression profile). Therefore,
ΔΔCt =ΔCt (tumor group) −ΔCt (control group) [8].
Relative quantification of miRNA expression was calcu-
lated with 2-ΔΔCt method, which represents relative fold
changes of miRNA expression.
Statistical analysis
The patients’ demographics for continuous variables
were reported as mean ± SD, while percentage, and
frequency calculated for categorical variables. Paired
Student’s t-test was used to determine the level of sig-
nificance (P < 0.05). Conditional logistic regression
model was used to calculate odds ratio with 95% con-
fidence interval to estimate association and control
the potential confounding variables, confirming diag-
nostic use of miRNAs that contributes to CRC prob-
ability. Discriminant analysis for classification of
tissues types [9] was performed to determine the dis-
criminative ability of the screened miRNAs. Statistical
analysis was performed using IBM SPSS version 16.0
software. P values of less than 0.05 were considered
statistically significant.
Results
Clinicopathological characteristics of CRC patients
The clinicopathological factors of the 32 (16 women)
participants with CRC recruited to the study are
showed in Table 1. The mean age of the respondents
was 31.3 years (±5.6 SD). No participants showed evi-
dence of disease complications. A total of 23 partici-
pants (71.9%) were within the age range of 60 years to
83 years, while9 patients (28.1%) were in the age range
of 20 years to 60 years. In addition, 16 participants
(50%) had stage II disease, while the other 16 (50%)
were diagnosed with stages III and IV disease. Although
Beştaş R et al. suggested that vascular endothelial
Table 1 Clinicopathological characteristics of CRC
patients

















Peng et al. BMC Cancer  (2015) 15:158 Page 3 of 7growth factor (VEGF) expression is significantly corre-
lated with advanced stage [10], we did not found any
correlation in this study. Among nine patients reported
VEGF, 4 patients (44.44%) were negative in VEGF and
5 out of them were positive. Loss of CK20 expression is
associated with poorly differentiated carcinoma [11].
Ten (31.3%) out of 31 patients were positive in CK20.Figure 1 Fold change of 96 selected miRNAs further validated by TaqMan RT
hsa-miR-592, hsa-miR-200a, hsa-miR-429, hsa-miR-183, hsa-miR-182, hsa-miR-1
whereas 84 miRNAs (hsa-miR-1, hsa-miR-145, hsa-miR-145*, and so on) were dFold change of 96 selected miRNAs further validated by
TaqMan RT-qPCR
To identify miRNAs that are differentially expressed
in tissues, we analyzed expression profiles of 1448
miRNAs, founding 497 miRNAs expression profiles
showed statistical significance, in which 155 miRNAs
have statistical significance in paired t-test and satis-
fied the strict condition of P ≤ 0.001.
To further validate the expression levels of these miR-
NAs, 31 patients were qualified and selected for per-
forming qPCR validation phase. In the condition of fold
chang >2.0 and P < 0.05, we gained a set of 96 miRNAs
that were differentially expressed between the colorectal
tissues and normal tissues, which were consistent with
the results of TaqMan Human MicroRNA Array. Twelve
miRNAs were upexpressed, while 84 miRNAs (has-miR-
137, hsa-miR-133a, hsa-miR-143, hsa-miR-363, hsa-miR-
4770, hsa-miR-490-5p, hsa-miR-133b, and so on) were
deexpressed in tumors compared with those in normal
tissues (adjusted P = 0.05) (Figure 1).
Selected miRNA expression levels in CRC tissues and
neighboring noncancerous tissues
After a series of selection processes independently with
enter method and conditional forward method in condi-
tional logistic regression, we found nine statistically sig-
nificant miRNAs in enter method, namely, miR574-3p,
miR422a, miR490-3p, miR-374b, miR-133a, let7g, miR-
378*, miR-9* and miR-378i.
On the other hand, we found seven statistically signifi-
cant miRNAs, namely, miR-145, miR-363, miR-378*,-qPCR. Twelve miRNAs (hsa-miR-130b, hsa-miR-203, hsa-miR-1974,
290, hsa-miR-141, hsa-miR-135b, and hsa-miR-96) were overexpressed,
ownexpressed in tumor tissues compared with those in normal tissues.
Figure 2 Selected miRNA expression levels in CRC tissues and neighboring noncancerous tissues. Selected miRNAs showed statistical significance in
conditional logistic regression analysis. (A) has-miR874-3p, miR422a, and miR490-3p expression levels in CRC tissues and neighboring noncancerous
colorectal tissues. (B) has-miR374b, has-miR133a, has-let-7 g, has-miR378, has-miR9*, and has-miR378i expression levels in CRC tissues and neighboring
noncancerous colorectal tissues.
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forward method. This result was consistent with Pagliu
A. et al.’s study who found that analysis of the combined
action of miR-143 and miR-145 on oncogenic pathways
in colorectal cancer cells reveals a coordinate program
of gene repression [12]. Besides, the expression levels of
these miRNAs between CRC tissues and the neighboring
noncancerous colorectal tissues were compared using
qRT-PCR analysis. Preliminary results showed that the
level of miR874-3p, miR-422a, miR-490-3p, miR-374b,
miR-133a, let-7 g, miR-378, miR-9*, and miR-378i were
all deregulated in the CRC tissues compared with the
neighboring noncancerous colorectal tissues (all P <
0.05) (Figure 2).Logistic regression and fold change of miR-145 in
different clinical stages
To further screen the most contribution factors to CRC
among these miRNAs, the variables above were used to
analyze in the conditional logistic regression. The results
indicated that miR-378* is the kept variable with statis-
tical significance to distinguish CRC from normal tissuesTable 2 Conditional logistic regression for the relationship be
Variable Coefficient Standard error
hsa-miR-378* 1.525 0.663
hsa-miR-145 1.438 0.653(P < 0.05; odds ratio = 4.6; 95% CI of odds ratio = 1.25 to
16.84). Similarly,miR145 is also the kept variable with
statistical significance to distinguish CRC from normal
tissues (P < 0.05; odds ratio = 4.21; 95% CI of odds ratio =
1.17 to 15.13) (Table 2). These results were consistent
with those from the study of Zhang et al., who indicated
that miRNA378 is a reliable, hemolysis-independent bio-
marker for CRC [13]. We compared the expression of
miR-378* in different clinical stages and found that miR-
378* is downregulated in all stages. A previous study also
proved that the expression of miR-378a-3p and miR-
378a-5p was significantly associated with TNM stage
[14]. These results indicate that clinical stage may influ-
ence the expression of miRNAs (Figure 3).Discriminant analysis for miR-378*
To verify the diagnostic value of miR-378*, Fisher dis-
criminant analysis was analyzed to predict the category
and determine the diagnostic ability of miR-378*. After
ln-gamma transformation of the sample data, the vari-
ables followed normal distributions and equal variance
matrix for categories I and II.tween miRNAs and CRC
Wald P value Odds ratio 95% CI
5.297 0.021 4.596 1.25 to 16.84
4.853 0.028 4.210 1.17 to 15.13
Figure 3 Fold change of miR-378* and miR-145 in different clinical stages. Expression levels of miR-378* and miR-145 varied in different clinical
stages.
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80.65% and false-positive rate is 19.35%. The whole dis-
criminant analysis results are listed in Table 3.
Receiver operator characteristic curve for miR-378* and
miR-145
Area under the curve for the receiver operator charac-
teristic function for miR-378* and miR-145 were 0.975
(95% confidence interval 0.923–1.00, p < 0.0005) and
0.996 (95% confidence interval 0.982–1.00, p < 0.0005)
separately. At an optimal cut score of ≥3.80 and < −1.975
(fold change 0.025) separately, sensitivity was 100% both
and specificity was 60% and 98% separately. A score of
−1.167 (fold change 0.833) or greater for miR-145 had
93.3% specificity but had sensitivity of only 93.8% (See
Figure 4, Table 4).
Discussion
Interestingly, our results in CRC samples agree with
those obtained by Faltejskova P et al., who found thatTable 3 Discriminant analysis results
Original
group
Prediction Total Error rate (%)
Tumor Normal
Tumor 25 6 31 19.35
Normal 6 25 31 19.35
Total 31 31 62 19.35the miRNAs functioning as tumor suppressors in CRC
are miR-378, miR-375, miR-422a, and miR-215 from 667
miRNAs in a paire design study [15]. Furthermore, Cui
SY et al. found that microRNA-145 as a potent tumour
suppressor that regulates multiple cellular pathways [16].
Zhang GJ et al. also indicated that miR-378 is an inde-
pendent prognostic factor that inhibits cell growth and
invasion in CRC. Most important is HouY et al. suggest
that microRNA-145 as ideal biomarker for the diagnosis
of various carcinomas [17].
Notably, our current study showed that discriminant
analysis based on expression data revealed that miR-
378* can distinguish CRC from normal tissues. This re-
sult is important for the potential role of new molecular
gene miR-378* in future diagnostic processes in the ab-
sence of effective early diagnostic biomarkers.
The different biological effects of any particular
miRNA in different cells could be dependent of the cell-
specific collection in target genes [18]. miR-378 inhibits
progression of human gastric cancer MGC-803 cells by
targeting MAPK1 in vitro [19]. miR-378 also promotes
BMP2-induced osteogenic differentiation of mesenchy-
mal progenitor cells [20]. Furthermore, miRNA-profiling
study proved that miR-378 was significantly upregulated
in cachexia related to enhanced adipocyte lipolysis in
human cancer [21]. Notably, Panza A, et al., found that
miR-145 is a novel target of PPARγ, acting as a tumor
suppressor in CRC cell lines and being a key regulator of
Figure 4 Receiver operator characteristic curve for miR-378* and miR-145 for the predictor of CRC.miRNA-378* levels had areas under the receiver
operator characteristic curve of 97.5% and 99.6% separately.
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a marker of undifferentiated progenitors in the colonic
crypts [22].
Therefore, high-field miR-378* and miR-145 are power-
ful means for investigating early CRC signs and are















37.90 100 0.0 −11.084 100 0.0
12.52 100 7.7 −8.427 100 0.1
7.02 100 13.3 −6.117 100 0.1
5.89 100 20.0 −5.166 100 0.2
5.70 100 16.7 −4.489 100 0.3
5.28 100 33.3 −3.919 100 0.3
4.93 100 40.0 −3.717 100 0.4
4.31 100 46.7 −3.390 100 0.5
3.82 100 53.3 −3.063 100 0.5
3.80 100 60.0 −2.864 100 0.6
3.43 93.8 60.0 −2.495 100 0.7
2.39 93.8 66.7 −2.294 100 0.7
1.82 93.8 73.3 −1.975 100 0.8
−1.167 93.8 0.9
−0.082 93.8 1.0Future validation of these methods is preparing planned
on a prospective study. Thus, previous studies reveals
that change of miR-378 expression has been previously
reported in nasopharyngeal cancer. Yu BL et al. reported
that repressing TOB2 expression would cause miR-378
to function as an oncomiR in nasopharyngeal carcinoma
[23]; miR-378/ATP also binds Cassette Transporter G1-
Signaling pathway [24].
Conclusions
In summary, our real-time PCR results identified alter-
ations of miRNA expression in CRC with two down-
regulated miRNAs (miR-378* and miR-145), which may
be novel candidate biomarkers for CRC. Although, both
miR-145 and miR-378* contribute to the probability of
CRC, comparison between the roles of miR-145 and miR-
378* in the CRC progression will give more information to
the cell transcription mechanisms.
Further mechanistic studies focusing on miR-378* and
miR-145 are required to investigate its underlying roles in
the tumorigenesis of CRC [24].
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